Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
作者信息
Batchelor T T, Grossman S A, Mikkelsen T, Ye X, Desideri S, Lesser G J
机构信息
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.
Abstract
摘要
相似文献
1
Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.
2
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Clin Transl Oncol. 2007 Jul;9(7):465-7. doi: 10.1007/s12094-007-0086-4.
3
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Yonsei Med J. 2011 Nov;52(6):1031-4. doi: 10.3349/ymj.2011.52.6.1031.
4
Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Leuk Lymphoma. 2014 Mar;55(3):471-3. doi: 10.3109/10428194.2013.830306. Epub 2013 Nov 14.
5
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Leuk Lymphoma. 2007 May;48(5):1019-22. doi: 10.1080/10428190701248009.
6
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Neurology. 2015 Feb 17;84(7):758-9. doi: 10.1212/01.wnl.0000461333.55612.f2.
7
Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Leuk Lymphoma. 2014 Mar;55(3):509-14. doi: 10.3109/10428194.2013.811239. Epub 2013 Jul 29.
8
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.
9
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13.
10
Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.
Infection. 2014 Apr;42(2):445-7. doi: 10.1007/s15010-013-0579-8. Epub 2014 Jan 20.
引用本文的文献
1
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma.
Blood Cancer J. 2025 Apr 29;15(1):81. doi: 10.1038/s41408-025-01278-w.
2
Optimization and Validation of the Cationization Method for the Fab' Fragment of Antibody Rituximab.
ACS Omega. 2025 Mar 26;10(13):12880-12890. doi: 10.1021/acsomega.4c07727. eCollection 2025 Apr 8.
3
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma.
Neurooncol Adv. 2024 Dec 11;7(1):vdae220. doi: 10.1093/noajnl/vdae220. eCollection 2025 Jan-Dec.
4
Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251319394. doi: 10.1177/15330338251319394.
5
Rituximab in the Treatment of Non-Infectious Uveitis: A Review.
J Inflamm Res. 2024 Sep 29;17:6765-6780. doi: 10.2147/JIR.S477708. eCollection 2024.
6
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
Clin Cancer Res. 2024 Sep 13;30(18):4005-4015. doi: 10.1158/1078-0432.CCR-24-0605.
7
HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.
Front Immunol. 2024 May 16;15:1376456. doi: 10.3389/fimmu.2024.1376456. eCollection 2024.
8
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.
Leukemia. 2024 Jul;38(7):1541-1552. doi: 10.1038/s41375-024-02279-7. Epub 2024 May 15.
9
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
Blood. 2024 Jul 25;144(4):457-461. doi: 10.1182/blood.2024024168.
10
Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
Ann Hematol. 2024 Mar;103(3):935-946. doi: 10.1007/s00277-023-05596-6. Epub 2023 Dec 29.
本文引用的文献
1
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Neuro Oncol. 2009 Aug;11(4):423-9. doi: 10.1215/15228517-2008-108. Epub 2008 Dec 5.
2
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
J Clin Oncol. 2007 Oct 20;25(30):4730-5. doi: 10.1200/JCO.2007.12.5062.
3
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.
Eur J Haematol. 2005 Apr;74(4):348-52. doi: 10.1111/j.1600-0609.2004.00401.x.
4
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Neurology. 2004 Sep 14;63(5):901-3. doi: 10.1212/01.wnl.0000137050.43114.42.
5
Response criteria for phase II studies of supratentorial malignant glioma.
J Clin Oncol. 1990 Jul;8(7):1277-80. doi: 10.1200/JCO.1990.8.7.1277.
Zotero 插件